U.S. Tech Hardware Stock News

NasdaqGS:ITRN
NasdaqGS:ITRNCommunications

Stronger Earnings And Bigger Capital Returns Could Be A Game Changer For Ituran (ITRN)

Ituran Location and Control Ltd. recently reported higher fourth‑quarter and full‑year 2025 earnings, approved a US$1.50 per‑share cash dividend totaling about US$30.00 million to be paid on April 16, 2026, and completed a US$25.42 million share buyback while authorizing an additional US$10.00 million for repurchases. The combination of earnings growth, a sizable dividend drawn from “Preferred Income” and “Preferred Technological Income” at a reduced 20% withholding tax rate, and an expanded...
NasdaqGS:DYN
NasdaqGS:DYNBiotechs

Is Dyne’s Phase 3 HARMONIA Launch Reframing The Investment Case For Dyne Therapeutics (DYN)?

Dyne Therapeutics recently advanced its neuromuscular pipeline, initiating the global Phase 3 HARMONIA trial of z-basivarsen for myotonic dystrophy type 1 and releasing new 24‑month data from the Phase 1/2 DELIVER trial of z-rostudirsen in Duchenne muscular dystrophy, alongside reporting a full-year 2025 net loss of US$446.21 million. With FDA alignment on HARMONIA’s confirmatory design, multiple regulatory designations for both assets, and additional long-term cardiopulmonary data in DMD,...
NYSE:IBM
NYSE:IBMIT

IBM Quantum Centric Architecture Aims To Reshape Enterprise AI And Security

IBM (NYSE:IBM) has introduced what it calls the industry's first quantum centric supercomputing architecture, a blueprint for combining quantum and classical systems. The company also expanded partnerships in quantum safe cybersecurity with Bain & Company and in AI infrastructure with NVIDIA. These announcements reflect IBM's focus on quantum, AI and security solutions for enterprise clients. IBM shares trade at $249.25, with the stock up 119.4% over the past 3 years and 144.0% over 5...
NasdaqGS:LFCR
NasdaqGS:LFCRLife Sciences

Lifecore Biomedical (LFCR) Q4 Loss Narrows To US$2 Million Reinforcing Bullish Margin Narratives

Lifecore Biomedical (LFCR) just posted its FY 2025 fourth quarter numbers, with revenue of US$36.4 million and a basic EPS loss of US$0.06. This sets the tone for a year where the trailing twelve months show revenue at about US$129.5 million and a basic EPS loss of US$0.92. Over recent quarters, revenue has moved from US$24.7 million in Q1 FY 2025 to US$31.1 million in Q3 and then US$36.4 million in Q4. Quarterly basic EPS losses ranged from US$0.53 in Q1 to US$0.29 in Q3 and US$0.06 in Q4,...
NasdaqGS:TRS
NasdaqGS:TRSPackaging

Assessing TriMas (TRS) Valuation After Recent Share Price Momentum And Undervaluation Narrative

Why TriMas is on investors’ radar today TriMas (TRS) has drawn fresh interest as investors look at its recent share performance alongside its value score of 3 and current market capitalization of about US$1.32b. The stock shows a 1 day return of 1.23%, a month return decline of 2.21%, and a past 3 months return of 3.77%, while the 1 year total return stands at 42.54%. See our latest analysis for TriMas. The recent 1 day share price gain of 1.23% to US$35.47 comes after a weaker 7 day and year...
NYSE:BABA
NYSE:BABAMultiline Retail

A Look At Alibaba Group Holding’s Valuation As Mixed Shareholder Returns Raise Questions

What Alibaba Group Holding (NYSE:BABA) offers investors right now Alibaba Group Holding (NYSE:BABA) gives you exposure to a broad ecosystem that spans e-commerce marketplaces, logistics, cloud computing, digital media, local services, healthcare, and collaboration tools across China and international markets. See our latest analysis for Alibaba Group Holding. Alibaba’s recent share price shows mixed momentum, with a 1 day share price return of 1.11% and a 7 day share price return of 3.07%,...
NasdaqGS:AMLX
NasdaqGS:AMLXPharmaceuticals

How Investors May Respond To Amylyx Pharmaceuticals (AMLX) Narrowed 2025 Losses And Expanded Shelf Capacity

In March 2026, Amylyx Pharmaceuticals reported fourth-quarter and full-year 2025 results showing a reduced net loss of US$33.0 million for the quarter and US$144.74 million for the year, alongside narrower basic losses per share, and filed new shelf registrations covering common and preferred stock, debt, warrants, and units. An interesting angle is that Amylyx paired this improvement in reported losses with fresh shelf capacity, potentially increasing its flexibility to fund pipeline and...
NasdaqGS:CRDO
NasdaqGS:CRDOSemiconductor

Is It Too Late To Consider Credo Technology Group Holding (CRDO) After Its 12-Month Surge?

Investors may be wondering if Credo Technology Group Holding at around US$116.88 is still offering value after such a strong run, or if enthusiasm has already been priced in. The stock has returned 0.8% over the last week, a 3.8% decline over 30 days, an 18.4% decline year to date and a 148.6% gain over the past year, with a very large 3 year return that is well over 10x. These moves have kept Credo on the radar for investors who focus on price momentum and shifts in sentiment. Recent...
NYSE:AIR
NYSE:AIRAerospace & Defense

AAR’s New Air Force Contract Adds Longer Term Government Revenue Visibility

AAR Manufacturing LLC, a unit of AAR Corp. (NYSE:AIR), has been awarded a long term contract with the U.S. Department of War. The agreement covers repair of the 463L Legacy Cargo Pallet system for the U.S. Air Force through 2031. The contract extends AAR’s government services work beyond its existing commercial-focused operations. For investors watching NYSE:AIR at a current share price of $105.64, this contract adds a fresh data point to an already strong share price run, with the stock up...
NYSE:LTC
NYSE:LTCHealth Care REITs

Is LTC Properties (LTC) Offering Value After Strong Multi Year Share Price Gains

If you are wondering whether LTC Properties at around US$38.99 is offering good value today, it helps to step back and look at what the recent share performance and fundamentals are really telling you. The stock has delivered a 0.6% return over the last week, a 1.0% decline over the past month, and is up 12.5% year to date and 15.5% over the past year, with longer term returns of 41.0% over three years and 26.1% over five years. Recent attention on LTC Properties has focused on its position...
NYSE:ED
NYSE:EDIntegrated Utilities

Does New US$3.5 Billion Credit Line And EPS Targets Change The Bull Case For Consolidated Edison (ED)?

Consolidated Edison recently entered into a new US$3.50 billions revolving credit facility to support its commercial paper programs and general corporate purposes, shortly after reporting Q4 2025 revenue and adjusted EPS that topped Wall Street expectations. Together with management’s plans for a five-year adjusted EPS compound annual growth rate of 6% to 7%, the expanded credit access highlights how the utility is prioritizing both liquidity and earnings visibility. We’ll now look at how...
NasdaqGS:AVGO
NasdaqGS:AVGOSemiconductor

Assessing Broadcom (AVGO) Valuation After Surging AI Semiconductor Growth And New AI Infrastructure Launches

Broadcom (AVGO) is in focus after a series of AI related announcements, including reports of rapid growth in AI semiconductor revenue, the introduction of the new Taurus 400G optical DSP and Tomahawk 6 switches, and new work on open optical standards. See our latest analysis for Broadcom. Even with all the AI headlines, Broadcom’s recent share price performance has cooled, with a 7 day share price return of a 6.02% decline and a 90 day share price return of a 4.80% decline, while the 1 year...
NYSE:BEKE
NYSE:BEKEReal Estate

KE Holdings (NYSE:BEKE) Margin Compression Tests Premium P/E And Bullish Growth Narrative

KE Holdings (NYSE:BEKE) FY 2025 Results Overview KE Holdings (NYSE:BEKE) has wrapped up FY 2025 with fourth quarter revenue of C¥22.2b and basic EPS of C¥0.08, alongside trailing 12 month revenue of C¥94.6b and basic EPS of C¥2.70 that frame the latest print for investors watching the stock around C¥16.90 per share. The company has seen quarterly revenue range from C¥22.1b to C¥26.0b over the past year, with basic EPS moving between C¥0.08 and C¥1.16 across FY 2025. This gives a clearer view...
NasdaqCM:OPAL
NasdaqCM:OPALOil and Gas

OPAL Fuels (OPAL) Thin 0.2% Margin Tests Bullish Profitability Narratives

OPAL Fuels (OPAL) has capped FY 2025 with fourth quarter revenue of US$99.8 million and basic EPS of US$0.08, setting a clean reference point for how its earnings story is developing. Over the past year, the company has seen quarterly revenue range from US$80.0 million to US$99.8 million and basic EPS move from a small loss of US$0.01 in Q1 2025 to positive readings in each subsequent quarter, giving you a clearer view of how the income line is tracking into year end. With trailing net profit...
NYSE:NOW
NYSE:NOWSoftware

A Look At ServiceNow (NOW) Valuation After New AI Partnerships And Product Launches

ServiceNow (NOW) is back in focus after rolling out several AI powered products and partnerships across government, telecom, healthcare, and security, giving investors fresh context for assessing the software group’s recent volatility. See our latest analysis for ServiceNow. Despite this steady stream of AI partnerships and product launches across government, telecom, and healthcare, ServiceNow’s 30 day share price return of 7.28% sits against a 90 day share price return decline of 26.46% and...
NYSE:EFC
NYSE:EFCMortgage REITs

A Look At Ellington Financial’s Valuation After Recent Share Price Weakness

Event context and recent performance Ellington Financial (EFC) has recently drawn attention after a period where the stock showed a return of about 1.2% over the past week, compared with weaker moves over the month and past 3 months. See our latest analysis for Ellington Financial. At a share price of $11.94, Ellington Financial has seen short term momentum soften, with a 30 day share price return of a 7.7% decline and a year to date share price return of a 12.7% decline. However, the 3 year...
NYSE:ABBV
NYSE:ABBVBiotechs

What AbbVie (ABBV)'s Early ABBV-295 Obesity Data Means For Shareholders

Earlier this month, AbbVie reported positive Phase 1 multiple-ascending-dose results for its investigational obesity drug ABBV-295, a long-acting amylin analog that induced clinically meaningful, dose-dependent weight loss with generally mild gastrointestinal side effects over 12–13 weeks of treatment. The data highlight AbbVie’s push into a mechanistically distinct class of obesity therapies beyond incretin-based drugs, adding another potential pillar to its already broad pipeline in...
NYSE:ZEPP
NYSE:ZEPPElectronic

Zepp Health (ZEPP) Q4 Loss Narrows To US$0.69 EPS Challenging Bearish Profitability Narratives

Zepp Health (ZEPP) has wrapped up FY 2025 with fourth quarter revenue of US$85.2 million and a basic EPS loss of US$0.69, setting the tone for how you might read the full year at the current share price of US$16.22. The company has seen quarterly revenue move from US$59.5 million in Q4 2024 to US$85.2 million in Q4 2025, while basic EPS over that stretch has shifted from a loss of US$2.29 to a loss of US$0.69. This puts the focus squarely on how sustainably margins can tighten those losses...
OTCPK:DIDI.Y
OTCPK:DIDI.YTransportation

A Look At DiDi Global (OTCPK:DIDI.Y) Valuation After Revenue Growth And Softer Profitability

Why DiDi Global’s latest earnings matter for shareholders DiDi Global (OTCPK:DIDI.Y) has released fourth quarter and full year 2025 results, with higher reported sales alongside a quarterly net loss and lower annual net income, giving you a mixed profitability picture to weigh. For the fourth quarter, DiDi Global reported sales of CNY 58,445 million compared with CNY 52,914 million a year earlier, and a net loss of CNY 338 million versus a CNY 1,341 million loss in the prior year...
NasdaqGS:ROST
NasdaqGS:ROSTSpecialty Retail

Ross Stores Expansion Tests Off Price Model And Community Focus In 2026

Ross Stores (NasdaqGS:ROST) is opening 17 new locations across 11 U.S. states as part of its 2026 expansion plan. The openings mark the first phase of a targeted 110 new stores the company aims to add this fiscal year. Each grand opening includes charitable contributions to local youth organizations in the surrounding communities. Ross Stores operates off price retail banners that focus on discounted apparel and home goods, a segment that often attracts value oriented shoppers. The decision...
NasdaqGS:ZION
NasdaqGS:ZIONBanks

Zions Leads Varex Refinancing As Valuation And Fee Potential Draw Focus

Zions Bancorporation National Association acted as lead arranger and bookrunner on Varex Imaging Corporation's new $490 million Credit and Guaranty Agreement. The bank will also serve as administrative and collateral agent for the syndicated credit facility. The transaction highlights Zions' role in complex corporate lending and syndicated loan coordination. Zions Bancorporation (NasdaqGS:ZION) is drawing attention for its role in a sizeable $490 million credit refinancing for Varex...
NYSE:VRT
NYSE:VRTElectrical

A Look At Vertiv (VRT) Valuation After S&P 500 Inclusion And Strong AI Data Center Results

Vertiv Holdings Co (VRT) has been added to the S&P 500, following quarterly results where earnings and net sales beat expectations, guidance for 2026 was raised, and demand for its AI focused data center solutions featured prominently. See our latest analysis for Vertiv Holdings Co. Vertiv's recent S&P 500 inclusion and AI focused product and partnership announcements have come alongside strong momentum, with a 30 day share price return of 12.88% and a 1 year total shareholder return...
NYSE:ACN
NYSE:ACNIT

Assessing Accenture (ACN) Valuation After A Year Of Share Price Weakness

Recent performance snapshot for Accenture stock Accenture (ACN) has drawn investor attention after a period of weaker share performance, with the stock down about 11% over the past month and 27% over the past 3 months. Over the past year, Accenture's total return shows a 37% decline, while the year to date move sits at 23% lower, setting the context for how the current US$199.31 share price is being assessed. See our latest analysis for Accenture. Short term momentum has weakened, with a 7...
NasdaqGS:EXLS
NasdaqGS:EXLSProfessional Services

Is EXL’s New Agentic AI Suite Reframing the Long-Term Competitive Narrative for ExlService (EXLS)?

In March 2026, EXL launched an expanded suite of agentic AI solutions, upgrading its EXLerate.ai, EXLdecision.ai, EXLdata.ai and domain-specific workflow tools such as EXL ClaimsAssist.ai to help enterprises move from AI experimentation to large-scale, measurable impact. A distinct aspect of this rollout is EXL’s integrated ecosystem, combining data readiness, no-code autonomous agent building, decision intelligence and embedded workflow automation, which aims to make AI deployment more...